Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

IQV vs VEEV vs DOCS vs MEDP

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
IQV
IQVIA Holdings Inc.

Medical - Diagnostics & Research

HealthcareNYSE • US
Market Cap$30.32B
5Y Perf.-26.3%
VEEV
Veeva Systems Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$27.35B
5Y Perf.-45.9%
DOCS
Doximity, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$5.24B
5Y Perf.-55.3%
MEDP
Medpace Holdings, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$12.24B
5Y Perf.+142.7%

IQV vs VEEV vs DOCS vs MEDP — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
IQV logoIQV
VEEV logoVEEV
DOCS logoDOCS
MEDP logoMEDP
IndustryMedical - Diagnostics & ResearchMedical - Healthcare Information ServicesMedical - Healthcare Information ServicesMedical - Diagnostics & Research
Market Cap$30.32B$27.35B$5.24B$12.24B
Revenue (TTM)$16.63B$3.20B$638M$2.68B
Net Income (TTM)$1.39B$909M$239M$460M
Gross Margin26.1%75.5%89.7%29.1%
Operating Margin13.9%28.7%37.4%21.0%
Forward P/E14.1x19.0x16.8x25.2x
Total Debt$16.17B$96M$12M$250M
Cash & Equiv.$1.98B$1.42B$210M$497M

IQV vs VEEV vs DOCS vs MEDPLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

IQV
VEEV
DOCS
MEDP
StockJun 21May 26Return
IQVIA Holdings Inc. (IQV)10073.7-26.3%
Veeva Systems Inc. (VEEV)10054.1-45.9%
Doximity, Inc. (DOCS)10044.7-55.3%
Medpace Holdings, I… (MEDP)100242.7+142.7%

Price return only. Dividends and distributions are not included.

Quick Verdict: IQV vs VEEV vs DOCS vs MEDP

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: DOCS and MEDP are tied at the top with 2 categories each — the right choice depends on your priorities. Medpace Holdings, Inc. is the stronger pick specifically for recent price momentum and sentiment and operational efficiency and capital deployment. IQV and VEEV also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
IQV
IQVIA Holdings Inc.
The Value Play

IQV is the clearest fit if your priority is value.

  • Lower P/E (14.1x vs 25.2x), PEG 0.35 vs 0.79
Best for: value
VEEV
Veeva Systems Inc.
The Income Pick

VEEV is the clearest fit if your priority is income & stability and sleep-well-at-night.

  • beta 0.77
  • Lower volatility, beta 0.77, Low D/E 1.3%, current ratio 4.89x
  • Beta 0.77, current ratio 4.89x
  • Beta 0.77 vs IQV's 1.33, lower leverage
Best for: income & stability and sleep-well-at-night
DOCS
Doximity, Inc.
The Growth Play

DOCS has the current edge in this matchup, primarily because of its strength in growth exposure and valuation efficiency.

  • Rev growth 20.0%, EPS growth 54.2%, 3Y rev CAGR 18.4%
  • PEG 0.21 vs VEEV's 1.04
  • 20.0% revenue growth vs IQV's 5.9%
  • 37.5% margin vs IQV's 8.3%
Best for: growth exposure and valuation efficiency
MEDP
Medpace Holdings, Inc.
The Long-Run Compounder

MEDP is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 14.4% 10Y total return vs VEEV's 5.2%
  • +42.9% vs DOCS's -55.4%
  • 24.8% ROA vs IQV's 4.7%, ROIC 154.9% vs 8.7%
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthDOCS logoDOCS20.0% revenue growth vs IQV's 5.9%
ValueIQV logoIQVLower P/E (14.1x vs 25.2x), PEG 0.35 vs 0.79
Quality / MarginsDOCS logoDOCS37.5% margin vs IQV's 8.3%
Stability / SafetyVEEV logoVEEVBeta 0.77 vs IQV's 1.33, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)MEDP logoMEDP+42.9% vs DOCS's -55.4%
Efficiency (ROA)MEDP logoMEDP24.8% ROA vs IQV's 4.7%, ROIC 154.9% vs 8.7%

IQV vs VEEV vs DOCS vs MEDP — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

IQVIQVIA Holdings Inc.
FY 2025
Research And Development Solutions
54.5%$8.9B
Technology And Analytics Solutions
40.6%$6.6B
Contract Sales And Medical Solutions
4.8%$788M
VEEVVeeva Systems Inc.
FY 2025
Subscription Services Veeva Research And Development
43.0%$1.2B
Subscription Services Veeva Commercial Cloud
40.2%$1.1B
Professional Services Veeva Research And Development
10.1%$277M
Professional Services Veeva Commercial Cloud
6.7%$185M
DOCSDoximity, Inc.
FY 2025
Subscription
95.3%$544M
Service, Other
4.7%$27M
MEDPMedpace Holdings, Inc.
FY 2025
Oncology
29.5%$748M
Metabolic
29.4%$745M
Other
16.1%$409M
Central Nervous System
10.1%$255M
Cardiology
9.5%$239M
Antiviral And Anti Infective
5.3%$135M

IQV vs VEEV vs DOCS vs MEDP — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMEDPLAGGINGVEEV

Income & Cash Flow (Last 12 Months)

DOCS leads this category, winning 4 of 6 comparable metrics.

IQV is the larger business by revenue, generating $16.6B annually — 26.1x DOCS's $638M. DOCS is the more profitable business, keeping 37.5% of every revenue dollar as net income compared to IQV's 8.3%. On growth, MEDP holds the edge at +26.5% YoY revenue growth, suggesting stronger near-term business momentum.

MetricIQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.MEDP logoMEDPMedpace Holdings,…
RevenueTrailing 12 months$16.6B$3.2B$638M$2.7B
EBITDAEarnings before interest/tax$3.5B$956M$250M$577M
Net IncomeAfter-tax profit$1.4B$909M$239M$460M
Free Cash FlowCash after capex$2.7B$1.4B$314M$745M
Gross MarginGross profit ÷ Revenue+26.1%+75.5%+89.7%+29.1%
Operating MarginEBIT ÷ Revenue+13.9%+28.7%+37.4%+21.0%
Net MarginNet income ÷ Revenue+8.3%+28.4%+37.5%+17.2%
FCF MarginFCF ÷ Revenue+16.1%+43.7%+49.2%+27.8%
Rev. Growth (YoY)Latest quarter vs prior year+8.4%+16.0%+9.8%+26.5%
EPS Growth (YoY)Latest quarter vs prior year+15.0%+23.9%-16.2%+16.6%
DOCS leads this category, winning 4 of 6 comparable metrics.

Valuation Metrics

IQV leads this category, winning 5 of 7 comparable metrics.

At 22.8x trailing earnings, IQV trades at a 26% valuation discount to VEEV's 30.9x P/E. Adjusting for growth (PEG ratio), DOCS offers better value at 0.30x vs VEEV's 1.70x — a lower PEG means you pay less per unit of expected earnings growth.

MetricIQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.MEDP logoMEDPMedpace Holdings,…
Market CapShares × price$30.3B$27.4B$5.2B$12.2B
Enterprise ValueMkt cap + debt − cash$44.5B$26.0B$5.0B$12.0B
Trailing P/EPrice ÷ TTM EPS22.79x30.92x23.45x28.06x
Forward P/EPrice ÷ next-FY EPS est.14.06x18.98x16.83x25.24x
PEG RatioP/E ÷ EPS growth rate0.56x1.70x0.30x0.88x
EV / EBITDAEnterprise value multiple12.97x28.40x21.14x21.31x
Price / SalesMarket cap ÷ Revenue1.86x8.56x9.18x4.84x
Price / BookPrice ÷ Book value/share4.67x3.89x4.84x27.57x
Price / FCFMarket cap ÷ FCF14.78x19.33x19.64x17.96x
IQV leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

MEDP leads this category, winning 4 of 8 comparable metrics.

MEDP delivers a 120.9% return on equity — every $100 of shareholder capital generates $121 in annual profit, vs $13 for VEEV. DOCS carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to IQV's 2.44x. On the Piotroski fundamental quality scale (0–9), DOCS scores 9/9 vs IQV's 4/9, reflecting strong financial health.

MetricIQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.MEDP logoMEDPMedpace Holdings,…
ROE (TTM)Return on equity+22.1%+13.4%+24.4%+120.9%
ROA (TTM)Return on assets+4.7%+11.1%+20.7%+24.8%
ROICReturn on invested capital+8.7%+12.9%+20.0%+154.9%
ROCEReturn on capital employed+11.0%+13.8%+22.3%+65.7%
Piotroski ScoreFundamental quality 0–94696
Debt / EquityFinancial leverage2.44x0.01x0.01x0.55x
Net DebtTotal debt minus cash$14.2B-$1.3B-$197M-$247M
Cash & Equiv.Liquid assets$2.0B$1.4B$210M$497M
Total DebtShort + long-term debt$16.2B$96M$12M$250M
Interest CoverageEBIT ÷ Interest expense3.10x
MEDP leads this category, winning 4 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

MEDP leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in MEDP five years ago would be worth $25,938 today (with dividends reinvested), compared to $4,911 for DOCS. Over the past 12 months, MEDP leads with a +42.9% total return vs DOCS's -55.4%. The 3-year compound annual growth rate (CAGR) favors MEDP at 27.0% vs DOCS's -8.8% — a key indicator of consistent wealth creation.

MetricIQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.MEDP logoMEDPMedpace Holdings,…
YTD ReturnYear-to-date-20.7%-23.4%-39.9%-24.9%
1-Year ReturnPast 12 months+16.5%-29.4%-55.4%+42.9%
3-Year ReturnCumulative with dividends-5.9%-5.2%-24.2%+104.6%
5-Year ReturnCumulative with dividends-23.8%-35.3%-50.9%+159.4%
10-Year ReturnCumulative with dividends+166.5%+519.4%-50.9%+1442.7%
CAGR (3Y)Annualised 3-year return-2.0%-1.8%-8.8%+27.0%
MEDP leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — IQV and VEEV each lead in 1 of 2 comparable metrics.

VEEV is the less volatile stock with a 0.77 beta — it tends to amplify market swings less than IQV's 1.33 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IQV currently trades 72.3% from its 52-week high vs DOCS's 34.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricIQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.MEDP logoMEDPMedpace Holdings,…
Beta (5Y)Sensitivity to S&P 5001.33x0.77x1.03x1.26x
52-Week HighHighest price in past year$247.05$310.50$76.51$628.92
52-Week LowLowest price in past year$134.65$148.05$20.55$284.48
% of 52W HighCurrent price vs 52-week peak+72.3%+54.2%+34.0%+68.2%
RSI (14)Momentum oscillator 0–10058.549.660.140.6
Avg Volume (50D)Average daily shares traded1.6M2.3M2.7M371K
Evenly matched — IQV and VEEV each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: IQV as "Buy", VEEV as "Buy", DOCS as "Buy", MEDP as "Hold". Consensus price targets imply 66.5% upside for VEEV (target: $280) vs 16.4% for MEDP (target: $499).

MetricIQV logoIQVIQVIA Holdings In…VEEV logoVEEVVeeva Systems Inc.DOCS logoDOCSDoximity, Inc.MEDP logoMEDPMedpace Holdings,…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyHold
Price TargetConsensus 12-month target$225.63$280.10$42.79$498.86
# AnalystsCovering analysts44422219
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises2
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap+4.1%+0.6%+2.3%+7.5%
Insufficient data to determine a leader in this category.
Key Takeaway

MEDP leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). DOCS leads in 1 (Income & Cash Flow). 1 tied.

Best OverallMedpace Holdings, Inc. (MEDP)Leads 2 of 6 categories
Loading custom metrics...

IQV vs VEEV vs DOCS vs MEDP: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is IQV or VEEV or DOCS or MEDP a better buy right now?

For growth investors, Doximity, Inc.

(DOCS) is the stronger pick with 20. 0% revenue growth year-over-year, versus 5. 9% for IQVIA Holdings Inc. (IQV). IQVIA Holdings Inc. (IQV) offers the better valuation at 22. 8x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate IQVIA Holdings Inc. (IQV) a "Buy" — based on 44 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — IQV or VEEV or DOCS or MEDP?

On trailing P/E, IQVIA Holdings Inc.

(IQV) is the cheapest at 22. 8x versus Veeva Systems Inc. at 30. 9x. On forward P/E, IQVIA Holdings Inc. is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Doximity, Inc. wins at 0. 21x versus Veeva Systems Inc. 's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

03

Which is the better long-term investment — IQV or VEEV or DOCS or MEDP?

Over the past 5 years, Medpace Holdings, Inc.

(MEDP) delivered a total return of +159. 4%, compared to -50. 9% for Doximity, Inc. (DOCS). Over 10 years, the gap is even starker: MEDP returned +1443% versus DOCS's -50. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — IQV or VEEV or DOCS or MEDP?

By beta (market sensitivity over 5 years), Veeva Systems Inc.

(VEEV) is the lower-risk stock at 0. 77β versus IQVIA Holdings Inc. 's 1. 33β — meaning IQV is approximately 72% more volatile than VEEV relative to the S&P 500. On balance sheet safety, Doximity, Inc. (DOCS) carries a lower debt/equity ratio of 1% versus 2% for IQVIA Holdings Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — IQV or VEEV or DOCS or MEDP?

By revenue growth (latest reported year), Doximity, Inc.

(DOCS) is pulling ahead at 20. 0% versus 5. 9% for IQVIA Holdings Inc. (IQV). On earnings-per-share growth, the picture is similar: Doximity, Inc. grew EPS 54. 2% year-over-year, compared to 4. 7% for IQVIA Holdings Inc.. Over a 3-year CAGR, MEDP leads at 20. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — IQV or VEEV or DOCS or MEDP?

Doximity, Inc.

(DOCS) is the more profitable company, earning 39. 1% net margin versus 8. 3% for IQVIA Holdings Inc. — meaning it keeps 39. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DOCS leads at 39. 9% versus 14. 0% for IQV. At the gross margin level — before operating expenses — DOCS leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is IQV or VEEV or DOCS or MEDP more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Doximity, Inc. (DOCS) is the more undervalued stock at a PEG of 0. 21x versus Veeva Systems Inc. 's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, IQVIA Holdings Inc. (IQV) trades at 14. 1x forward P/E versus 25. 2x for Medpace Holdings, Inc. — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 66. 5% to $280. 10.

08

Which pays a better dividend — IQV or VEEV or DOCS or MEDP?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is IQV or VEEV or DOCS or MEDP better for a retirement portfolio?

For long-horizon retirement investors, Medpace Holdings, Inc.

(MEDP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26), +1443% 10Y return). Both have compounded well over 10 years (MEDP: +1443%, IQV: +166. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between IQV and VEEV and DOCS and MEDP?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: IQV is a mid-cap quality compounder stock; VEEV is a mid-cap high-growth stock; DOCS is a small-cap high-growth stock; MEDP is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

IQV

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

VEEV

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 17%
Run This Screen
Stocks Like

DOCS

Quality Mega-Cap Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 22%
Run This Screen
Stocks Like

MEDP

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 13%
  • Net Margin > 10%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform IQV and VEEV and DOCS and MEDP on the metrics below

Revenue Growth>
%
(IQV: 8.4% · VEEV: 16.0%)
Net Margin>
%
(IQV: 8.3% · VEEV: 28.4%)
P/E Ratio<
x
(IQV: 22.8x · VEEV: 30.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.